← Eichor
Condition: Relapsing Multiple Sclerosis Rms Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsing Multiple Sclerosis Rms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Phase 2/Phase 3 · 2 location(s) · TG Therapeutics, Inc. · NCT07220252Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Se
Phase N/A · 1 location(s) · Third Affiliated Hospital, Sun Yat-Sen University · NCT07353216A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Mult
Phase N/A · 91 location(s) · TG Therapeutics, Inc. · NCT06433752An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Phase 1/Phase 2 · 18 location(s) · Novartis Pharmaceuticals · NCT06617793A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Mul
Phase N/A · 1 location(s) · Neurology Center of New England P.C. · NCT06681623Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)
NA · 1 location(s) · University of Southern California · NCT06515782A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescent
Phase 2 · 17 location(s) · Hoffmann-La Roche · NCT07161258A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Phase N/A · 138 location(s) · Novartis Pharmaceuticals · NCT05344469Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Scle
Phase 3 · 120 location(s) · Novartis Pharmaceuticals · NCT06846281A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms
Phase 1 · 35 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06220201An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Phase 1 · 19 location(s) · AstraZeneca · NCT07224373Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Phase N/A · 15 location(s) · Novartis Pharmaceuticals · NCT06486779Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Phase N/A · 10 location(s) · Novartis Pharmaceuticals · NCT05809986
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.